Opendata, web and dolomites

OsteomiR

OsteomiR-Test – An In-Vitro Test for the Diagnosis of Osteoporosis and associated Fracture Risk

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OsteomiR project word cloud

Explore the words cloud of the OsteomiR project. It provides you a very rough idea of what is the project "OsteomiR" about.

combining    fracture    disease    mineral    prevention    osteoporosis    successful    urgent    markets    strategy    structure    clinical    life    incidence    combination    age    basis    chronic    market    2050    tamirna    bone    good    association    metabolism    costly    standard    fractures    superior    constitute    micrornas    freedom    approval    drug    circulating    commercial    economic    stress    readout    regulatory    demonstrated    ivd    entry    consequently    commercialization    osteoporotic    performance    select    risk    depends    competiveness    samples    prioritize    union    meets    prognosis    operate    expectancy    specificity    commercialize    suitable    eur    skeletal    76    manufacturing    blood    limits    creates    strength    countries    direct    diet    treatment    proprietary    exercise    biological    diagnostic    predict    efficient    health    density    tests    launch    systemic    models    24    intended    vitro    osteomir    feasibility    conduct    billion    2004    scalability   

Project "OsteomiR" data sheet

The following table provides information about the project.

Coordinator
TAMIRNA GMBH 

Organization address
address: LEBERSTRASSE 20/8
city: WIEN
postcode: 1110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website http://www.tamirna.com/partners-investors.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TAMIRNA GMBH AT (WIEN) coordinator 50˙000.00

Map

 Project objective

TAmiRNA aims to commercialize an in-vitro diagnostic test that is intended to predict fracture-risk in case of osteoporosis. The OsteomiR-Test meets an urgent clinical need by combining superior diagnostic performance with a simple test principle, thus, ensuring cost competiveness, good scalability and commercial success. Osteoporosis is a chronic skeletal disease characterized by systemic loss of bone strength and consequently high incidence of bone fractures. Osteoporotic fractures constitute one of the most common and costly health problems in the European Union (EU): costs related directly to fractures were EUR 24.3 billion in 2004 and will rise to EUR 76.8 billion by 2050 due to increasing life expectancy. Effective fracture prevention can be achieved through exercise, diet and drug treatment, but depends on reliable early prognosis of fracture risk. Currently, bone mineral density and clinical factors are the basis for prognosis of fracture risk. However, the low specificity of these tests limits efficient fracture prevention and creates an urgent clinical need for novel and better tests. The OsteomiR-Test measures a proprietary combination of circulating microRNAs from standard blood samples. The analyzed microRNAs provide a direct readout of bone metabolism, stress and biological age, and have been demonstrated to have a strong association with fracture-risk. It is a robust, easy-to-use test with good scalability. In order to commercialize the OsteomiR-Test, a detailed assessment of a market entry strategy is required. Therefore, TAmiRNA will i) develop health economic models to prioritize EU-countries for market launch, (ii) identify suitable manufacturing and distribution partners, (iii) define a strategy for IVD regulatory approval and, (iv) conduct a freedom-to-operate analysis. The results of this feasibility study will help to select target markets and define the cost structure of the test, and are therefore essential to successful commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OSTEOMIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OSTEOMIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More